Tarsus Pharmaceuticals (TARS) Stock
Tarsus Pharmaceuticals (TARS) closed at $78.20 on Nov 17, 2026; its Tenet Score is 34 of 100 against 340 Healthcare peers.
21 figures withheld by our checks. Each blank figure names its reason.
Key stats
- Close
- $78.20
- Nov 17, 2026
- Market cap
- $3.9B
- share price × the latest quarter's diluted weighted-average share count (vendor)
- 52-week range
- 53.89 – 91.53
- low → high · as of close, Nov 16, 2026
- Tenet Score
- 34/100
- Weak · 340 Healthcare peers
Industry: Drugs
Tarsus Pharmaceuticals Inc scores 34/100. Weak. Strongest on growth, value is the soft spot versus 340 Healthcare peers.
Tenet Score · vs sector
n=340Factor grades
Price
The whole report, at a glance · every card is a live peek, click any to open the section
- ✕ Buffett Quality
- ✕ Piotroski F-Score
- ✕ Graham Defensive
- ✕ Quality Compounder
- ~ Drawdown Context
- ✓ Reversal Evidence
13F flows & insider trades land here.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase I…
Similar-sized companies in Drugs
The 10 companies in this industry closest in market cap, as of Nov 16, 2026.
| Company | Tenet Score | Market cap |
|---|---|---|
| Definium Therapeutics Inc.DFTX | 50 | $4.1B |
| CRISPR Therapeutics AGCRSP | 64 | $3.9B |
| Xenon Pharmaceuticals IncXENE | 44 | $3.9B |
| Relay Therapeutics IncRLAY | 43 | $3.8B |
| Organon & Co.OGN | 45 | $3.7B |
| Amylyx Pharmaceuticals IncAMLX | 56 | $3.6B |
| Enliven Therapeutics IncELVN | 60 | $3.5B |
| Iovance Biotherapeutics IncIOVA | 52 | $3.5B |
| Arcutis Biotherapeutics IncARQT | 43 | $3.4B |
| Viking Therapeutics IncVKTX | 36 | $3.4B |
Common questions
What sector and industry is Tarsus Pharmaceuticals in?
Tarsus Pharmaceuticals is in the Healthcare sector and the Drugs industry.
What is Tarsus Pharmaceuticals' Tenet Score?
Tarsus Pharmaceuticals' Tenet Score is 34 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.




